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The diterpene forskolin maximally stimulated bovine adrenal cortex adenylate cyclase activity 9-fold with 
a concentration producing half-maximum effect (EDm) of about 4 PM. The effects of forskolin and the fully 
active corticotropin fragment ACTH (l-24) were additive over nearly the whole range of concentration of 
both effecters, indicating separate and independent mechanisms of action. By contrast, 10 mM NaF blocked 
forskolin action in the nanomolar range of the diterpene concentration, while it allowed a partial stimulation 
by forskolin in the micromolar range. NaF thus reveals a heterogeneity of forskolin action in the adrenal 
cortex plasma membranes. Moreover, our data suggest hat ACTH and NaF activation effects, both mediat- 
ed by the stimulator-y regulatory protein G,, proceed through different mechanisms. 
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1. INTRODUCTION 
Bovine adrenal cortex plasma membranes con- 
tain an adenylate cyclase stimulated by cor- 
ticotropin (ACTH), the physiological hormone 
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dimethyl sulfoxide; DTE, dithioerythritol; BSA, bovine 
serum albumin 
regulating steroidogenesis. As in other systems, 
hormonal activation of the catalytic unit (C) of the 
cyclase implies hormone binding on its receptor [l] 
as well as the mediation of stimulatory regulatory 
GTP-binding proteins (G,) [2,3] which were 
demonstrated in this tissue by Glossmann and Gips 
[4,5]. These regulatory proteins have been shown 
to consist of three different protein subunits (Y, p 
and y for which an association-dissociation 
equilibrium is suggested to play a key role in the 
activation of the enzyme [6,7]. 
As a tool for investigating the coupling of the 
different components of the cyclase in the adrenal 
cortex plasma membranes, we have used forskolin, 
a diterpene described as a potent general activator 
of the enzyme [8,9], in particular in adrenals 
[lo-131. Forskolin acts directly on the catalytic 
unit and also interferes with the coupling 
mechanism of C with G, [14]. In this paper, the 
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stimulation characteristics of adenylate cyclase by 
forskolin were determined either with the diterpene 
alone or in combination with the fully active syn- 
thetic fragment of corticotropin [ACTH( l-24)], 
or with fluoride, a non-hormonal stimulatory 
ligand acting via G, [ 151. We demonstrate additivi- 
ty of forskolin and ACTH(l-24) stimulation of 
the enzyme, indicating independent mechanisms of 
action of these effecters. By contrast, we show 
partially exclusive effects of fluoride with for- 
skolin which suggests that hormone and fluoride 
may act in a different way through their common 
mediator G,. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
ATP, GTP, phosphoenolpyruvate, pyruvate 
kinase, PMSF, aprotinin and pepstatin were from 
Sigma. Forskolin was purchased from Calbio- 
them, NaF from Merck and DMSO from Fluka. 
ACTH(l-24) was a kind gift from Drs K. Scheibli 
and R. Andreatta (Ciba-Geigy, Basel). 
2.2. Plasma membrane preparation 
Bovine adrenal cortex plasma membranes were 
prepared by homogenizing 45 g of the cortex 
essentially as in [16] except for the buffer which 
contained 1 mM NaHCOs (pH 7.5), 1 mM DTE 
(buffer A), 0.25 M sucrose, 0.1 mM PMSF and 
0.2 mg aprotinin and pepstatin per g tissue. The 
homogenate was centrifuged at 1200 x g for 
10 min and the resulting supernatant at 15 000 x g 
for 20 min at 4°C. The pellet was rehomogenized 
in 45 ml of the same buffer without the protease 
inhibitors and layered on a discontinuous sucrose 
gradient [30.5% (w/w), 39.2 and 47.8% in a 
volume ratio of 1: 1.7 : 1 and a ‘cushion’ at 57%, 
in buffer A]. Centrifugations were run for either 
3 h at 25000 rpm in an SW 27 rotor or for 2 h at 
47000 rpm in a Ti 14 zonal rotor. The material at 
the 39.2-47.8% interface was diluted 6-fold in 
buffer A containing 20 mg aprotinin and pepstatin 
per g membrane protein. Membranes were 
harvested by centrifugation (48000 x g, 30 min) 
and resuspended in the last buffer plus 0.25 M 
sucrose at -5 mg protein/ml. Aliquots were stored 
in liquid nitrogen. 
This membrane preparation, set up from 
previous analysis [17], results in an 8.9 f 2.1-fold 
108 
enrichment in forskolin-stimulated adenylate 
cyclase activity relative to the homogenate with a 
24 + 1% yield (means + SD on 3 preparations). 
2.3. A denylate cyclase assays 
Adenylate cyclase activity was determined in 
40 mM Tris-HCl (pH 7.5) buffer containing 
25 mM phosphoenolpyruvate, 40 U pyruvate 
kinase/ml, 0.1% BSA, 5 PM GTP, 1 mM DTE, 
2.5 mM MgClz and 0.5 mM ATP as final concen- 
trations. Concentrations of added stimulators were 
as indicated in the figure legends. Forskolin was 
added from stock solutions in DMSO (final cosol- 
vent concentration 1070, v/v). Incubations were 
performed in 240 ~1 final volume containing from 
3 to 15 pg membrane proteins. After equilibration 
of the membranes in buffer (2 min at 30”(Z), the 
reaction was started by substrate addition and car- 
ried out at 30°C for 20 min. It was stopped by im- 
mersing the tubes for 70 s in a boiling water bath 
and the incubates were stored frozen before CAMP 
determination. Control samples were simulta- 
neously performed. 
CAMP was determined in duplicate for each in- 
cubate according to [ 181 using an Amersham assay 
kit. The deviates were -4% of the means. It was 
verified that the activity was linear with time and 
protein concentration under all conditions tested. 
Protein was determined according to [19] as 
modified in [20]. 
3. RESULTS 
The dose-response curve to forskolin stimula- 
tion of bovine adrenal cortex adenylate cyclase ex- 
tends over a wide range of concentrations of this 
effector, from 0.01 to 100 PM (fig.1, lower curve). 
The EDso value is 3.7 f 0.4rM (mean + SD on 3 
preparations) and the maximal stimulation factor 
k is 9.1 + 1.5 (n = 3). Forskolin efficacy is higher 
than that obtained for maximal response to 
ACTH(l-24) (k = 7.3 4 0.3, n = 2) or for 10 mM 
NaF (k = 7.1 + 0.1, n = 2). In this membrane 
preparation, the dose-response curve to 
ACTH(l-24) is characterized by an EDso of 0.18 
+ O.lO,uM (n = 2) (fig.2, lower curve). 
The combined effects of ACTH(l-24) and for- 
skolin were studied by determining the dose- 
response curves to one activator at a fixed concen- 
tration of the other and conversely (figs 1,2). In the 
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Fig.1. Dose-response curves for forskolin activation of 
adenylate cyclase activity from bovine adrenal cortex 
plasma membranes, in the absence (0) or presence of 
0.56 x lo*’ M (0) or 0.8 x lo-’ M ACTH(l-24) (m). 
The bars join the values obtained for duplicate 
incubations in 1 experiment. The dashed line represents 
the curve corresponding to complete additivity of ACTH 
(0.8 x 10m5 M) and forskolin effects. 
case of additivity of the two stimulators’ effects, a 
parallelism between the dose-response curves is ex- 
pected, the curves being only shifted upward to a 
higher activity. Such a parallelism is actually 
observed in fig.2 between the three dose-response 
curves to ACTH determined in the absence or 
presence of 0.1 or 5 ,uM forskolin. Therefore, com- 
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Fig.2. Dose-response curves for ACTH( l-24) activation 
of adenylate cyclase activity, in the absence (0) or 
presence of 0.1 pM (m) or 5 PM forskolin (0). The bars 
join the values obtained for duplicate incubations in 1 
experiment. The data are representative of 2 
experiments. 
plete additivity with ACTH effect is demonstrated 
at these concentrations, where forskolin alone 
elicited around 10 and 55% of its maximal effect, 
respectively (fig. 1). 
Similarly, a parallelism is observed between the 
dose-response curves to forskolin without or with 
0.56 x lo-’ M ACTH (fig.1) corresponding to 
about 20% of the hormone maximal effect. At 8 x 
10m6 M ACTH, where the hormone stimulation is 
maximal, the two activators add their effects up to 
a forskolin concentration between 1 and 10pM. 
Above that concentration, adenylate cyclase activi- 
ty further increases with increasing forskolin con- 
centration but in a less than additive way (dashed 
line in fig. 1). The maximum activity value obtain- 
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Fig.3. (Left) Dose-response curves for forskolin 
activation of adenylate cyclase activity in the absence 
(A) or presence of 10 mM NaF (A) or 0.8 x 10-s M 
ACTH(l-24) (+). At these concentrations, these last 
effecters produce their maximal effect. The bars join the 
values obtained for duplicate incubations in the same 
experiments. NaF effect is representative of 3 
experiments performed on 2 membrane preparations. 
(Right) Proposed schemes for adenylate cyclase 
activation in the bovine adrenal cortex plasma 
membranes; cys, a-subunit of the stimulatory regulatory 
protein G,; fl, &subunit of the regulatory protein G, C, 
C ’ C’ ’ and C ’ ’ ’ refer to the catalytic unit in different 
coAformationa1 states. ( q , n ) High-affinity forskolin- 
binding site, either unoccupied or ineffective (open 
symbol) or fully occupied (closed symbol); (0,0,0) low- 
affinity forskolin-binding site, unoccupied (open 
symbol), partially effective (half-filled symbol) or fully 
occupied (closed symbol). Scheme IV refers to the 
protein coupling model derived from the experiments of 
Gilman et al. (i.e. cY,-activated catalytic unit) (6,7] and 
scheme III to that proposed by Verkman et al. (i.e. ru& 
activated catalytic unit) [27]. 
ed at the highest dose of both ACTH and forskolin 
corresponds to a stimulation factor of 13.4 which 
can formally be interpreted as resulting from an 
addition of 100% of the ACTH effect and 7O(rlo f 
the forskolin effect. This slight non-additivity in 
the high forskolin concentration region increases 
the apparent potency of forskolin, the EDso value 
being shifted from 3.7 to 21 FM. 
Comparison of ACTH (8 x 10e6 M) and NaF 
(10 mM) effects on the dose-response curve to for- 
skolin demonstrates a divergence between the 
behaviour of these two effecters used at concentra- 
tions where they have initially similar activation ef- 
fects on adenylate cyclase activity in the absence of 
forskolin (fig.3, upper two curves). 
NaF and forskolin activation effects are never 
fully additive whatever the diterpene concentra- 
tion. NaF appears to block forskolin action in the 
low concentration range of the diterpene [at 
0.01 FM (not shown) and 0.1 FM (fig.3)] where the 
activity is even slightly depressed as compared to 
that obtained with fluoride alone. The activity then 
increases at higher forskolin concentrations, 
resulting in a maximum activity value which can be 
interpreted as the addition of 100% of the NaF ef- 
fect and 43 -t 29’0 (mean + SD on 3 expts) of the 
forskolin effect. 
4. DISCUSSION 
This report first describes forskolin stimulation 
characteristics of adenylate cyclase in bovine 
adrenal cortex plasma membranes. The EDso value 
(3.7 PM) is significantly smaller than that obtained 
in other membrane systems in which forskolin ac- 
tion is mostly characterized by an EDso around 
10pM. In addition, its efficacy is among the 
highest generally obtained in such systems 
(3-IO-fold stimulation over basal activity) 
[14,21,22]. This high potency and efficacy allows 
an accurate determination of the catalytic unit ac- 
tivity. Forskolin was used in this work to study the 
effect of the interaction of C (site of forskolin ac- 
tion) with the other protein components of the 
cyclase implicated in the stimulation by ACTH and 
fluoride. 
With respect to the combined effects of ACTH 
and forskolin, the data reported here demonstrate 
their exact additivity over nearly the whole range 
110 
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of both effector concentrations. Therefore, these 
compounds appear to act essentially by indepen- 
dent mechanisms in the adrenal membranes (as il- 
lustrated in fig.3, right). The additivity of 
forskolin and ACTH effects is not complete in the 
case of high concentrations of both effecters. This 
may be explained either by a partial impeding ef- 
fect of ACTH on forskolin action or because the 
high activation level of the enzyme approaches a 
maximal turnover that cannot be further 
augmented. The additivity observed differs from 
the potentiating effect of forskolin on hormone ac- 
tion described in intact cells 110,221. The absence 
of potentiation of hormone stimulation seems to 
be rather general in isolated membranes [ 141 except 
in some instances as for human platelets [23]. It 
could be suggested that the membrane preparation 
might remove or alter a cellular component in- 
volved in this potentiation. 
In contrast with the additive effects of ACTH 
and forskolin, the NaF (10 mM) and forskolin 
combination produces less than additive effects on 
adenylate cyclase activity, whatever the diterpene 
concentration. In that case, the non-additivity ob- 
served at high concentrations of both effecters 
cannot be due to a maximal turnover of the 
enzyme since higher activity values have been ob- 
served in the presence of both ACTH and fors- 
kolin. A correlated observation has been reported 
for rat cerebral cortical membranes where, in a 
converse experiment, non-additivity of forskolin 
and NaF effects was shown on the whole dose- 
response curve to fluoride [21]. Both experiments 
converge to indicate interference between the sites 
of action of NaF and forskolin. Moreover, the 
variation in degree of this interference with 
forskolin, concentration argues in favour of a 
heterogeneity of forskolin sites of action in these 
membranes. In this respect, recent binding studies 
have shown the existence of low- and high-affinity 
binding sites of forskolin in rat brain membranes 
[24], which might also occur in the adrenal mem- 
branes. NaF would prevent the stimulation due to 
forskolin binding on a high-affinity site 
(nanomolar range) while NaF stimulation would 
be partially additive with the stimulation due to a 
forskolin low-affinity binding site (fig.3, right). 
Such an effect of NaF in the adrenal membranes 
appears to be at variance with that observed in rat 
brain and human platelet membranes where NaF 
was shown to increase high-affinity binding sites 
for [3H]forskolin [25,26]. 
Our data show a divergence between hormone 
and fluoride effects on forskolin-activated 
adenylate cyclase. We have also demonstrated 
previously a divergence between the hormone- or 
fluoride-stimulated adenylate cyclase activity with 
regard to their temperature dependence 1131 as well 
as to their membrane fluidity dependence (un- 
published). These results are in line with recent 
observations of Verkman et al. [27], derived from 
target size analysis on intact cells which argue in 
favour of different mechanisms for hormone and 
fluoride action. While the hormone would act by 
promoting the liberation of the cu-subunit of G, 
which would in turn activate C (general mechanism 
hypothesized for Gs-mediated effects from studies 
in detergent solution [6]), fluoride may use the 
non-dissociated afl complex to activate C. Such a 
model is compatible with our data, the &subunit 
then being the component blocking forskolin ac- 
tion on a high-affinity site. A schematic represen- 
tation of adenylate cyclase activation in the 
adrenal cortex membranes (fig.3, right) sum- 
marizes the proposed conclusions. 
ACKNOWLEDGEMENTS 
B.F. gratefully acknowledges M. le Maire for 
helpful discussions. This work was supported by 
the Centre National de la Recherche Scientifique 
(ER 64-01) and the Institut National de la Sante et 
de la Recherche Mtdicale. 
REFERENCES 
[I] Schulster, D. and Schwyzer, R. (1980) in: Cellular 
Receptors for Hormones and Neuro-transmitters 
(Schulster, D. and Levitski, A. eds) pp.197-217, 
Wiley, New York. 
121 Limbird, L.E. (1981) Biochem. J. 195, 1-13. 
[3] Spiegel, A.M. and Downs, R.W. (1981) Endocr. 
Rev. 2, 275-305. 
[4] Glossmann, H. and Gips, H. (1974) Naunyn- 
Schmiedeberg’s Arch. Pharmacol. 286, 239-249. 
[5] Glossmann, H. (1975) Naunyn-Schmiedeberg’s 
Arch. Pharmacol. 289, 99-109. 
[6] Smigel, M.D., Katada, T., Northup, J-K., Bokoch, 
G.M., Ui, M. and Gilman, A.G. (1984) Adv. Cyclic 
Nucleotide Protein Phosphorylation Res. 17, 1-18. 
111 
Volume 216, number 1 FEBS LETTERS May 1987 
[7) Smigel, M.D., Ferguson, K.M. and Gilman, A.G. 
(1985) Adv. Cyclic Nucleotide Protein 
Phosphorylation Res. 19, 103-111. 
[8] Metzger, H. and Lindner, E. (1981) IRSC Med. 
Sci. 9, 99. 
[9] Seamon, K.B., Padgett, W. and Daly, J.W. (1981) 
Proc. Natl. Acad. Sci. USA 78, 3363-3367. 
[lo] Moriwaki, K., Itoh, Y., Iida, S. and Ichihara, K. 
(1982) Life Sci. 30, 2235-2240. 
[ll] Schimmer, B.P. and Tsao, J. (1984) J. Biol. Chem. 
259, 5376-5379. 
[12] Mikami, K., Nishikawa, T. and Strott, C.A. (1985) 
Biochem. Biophys. Res. Commun. 129, 664-670. 
[13] De Foresta, B., Rogard, M. and Gallay, J. (1986) 
Biochem. Sot. Trans. 14, 1011-1012. 
[14] Seamon, K.B. (1985) Drug Devel. Res. 6, 181-192. 
[15] Ross, E.M. and Gilman, A.G. (1980) Annu. Rev. 
Biochem. 49, 533-564. 
[16] Schlegel, W. and Schwyzer, R. (1977) Eur. J. Bio- 
them. 72, 415-424. 
[17] De Foresta, B., Rogard, M. and Gallay, J. (1984) 
Abstr., in: Organisation des Systemes Biologiques, 
3rd Annual Reunion of French Biophysical Society, 
November 5-7, Orsay, France. 
[18] Tovey, K.C., Oldham, K.G. and Whelan, J.A.M. 
(1974) Clin. Chim. Acta 56, 221-234. 
[19] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and 
Randall, R.J. (1951) J. Biol. Chem. 193, 265-275. 
[20] Markwell, M.A.K., Haas, S.M., Bieber, L.L. and 
Tolbert, N.E. (1978) Anal. Biochem. 87, 206-210. 
[21] Seamon, K.B. and Daly, J.W. (1981) J. Cyclic 
Nucleotide Res. 7, 201-224. 
[22] Daly, J.W. (1984) Adv. Cyclic Nucleotide Protein 
Phosphorylation Res. 17, 81-89. 
[23] Insel, P.A., Stengel, D., Ferry, N. and Hanoune, J. 
(1982) J. Biol. Chem. 257, 7485-7490. 
[24] Seamon, K.B., Vaillancourt, R., Edwards, M. and 
Daly, J.W. (1984) Proc. Natl. Acad. Sci. USA 81, 
5081-5085. 
[25] Seamon, K.B., Vaillancourt, R. and Daly, J.W. 
(1985) J. Cyclic Nucleotide Res. 10, 535-549. 
[26] Nelson, C.A. and Seamon, K.B. (1986) J. Biol. 
Chem. 261, 13469-13473. 
[27] Verkman, A.S., Ausiello, D.A., Jung, C.Y. and 
Skorecki, K.L. (1986) Biochemistry 25, 4566-4572. 
112 
